Key result
Self-expanding TPVR shows ~99% freedom from hemodynamic dysfunction and RVOT reintervention at one year.
Why the study?
Limited data are available on the safety and short-term effectiveness of self-expanding TPVR in real-world experience since U.S. FDA approval in 2021 for patients with RVOT pulmonary regurgitation.
Does transcatheter self-expanding pulmonary valve replacement improve hemodynamic function and prevent RVOT reintervention in patients with native or surgically repaired RVOT pulmonary regurgitation?
Observational (n=243)
Yes
Does transcatheter self-expanding pulmonary valve replacement improve hemodynamic function and prevent RVOT reintervention in patients with native or surgically repaired RVOT pulmonary regurgitation?
In a real-world multicenter registry, self-expanding TPVR demonstrated excellent short-term clinical and hemodynamic outcomes with 99% freedom from hemodynamic dysfunction or reintervention at 1 year.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“These Harmony results represent another big step in the evolution of interventional cardiology and will be up there with development of the Melody valve and the utility and the use of the Sapien valve in the pulmonary position.”
“One of the things that we've really needed, as a group of doctors that treats a relatively small market, is self-expanding valves that can act as pulmonary valve replacers for patients with large outflow tracts. Patients that we can't just put a Melody or a Sapien valve in.”
“The Harmony TPV therapy finally offered a non-surgical option to treat severe PR and restore pulmonary valve competence.”
Real-world data support self-expanding TPVR for native RVOT PR; leaves open long-term durability pending randomized comparisons.
BACKGROUND Transcatheter pulmonary valve replacement (TPVR) with the self-expanding Harmony valve (Medtronic) is an emerging treatment for patients with native or surgically repaired right ventricular outflow tract (RVOT) pulmonary regurgitation (PR). Limited data are available since U.S. Food and Drug Administration approval in 2021. OBJECTIVES In this study, the authors sought to evaluate the safety and short-term effectiveness of self-expanding TPVR in a real-world experience. METHODS This was a multicenter registry study of consecutive patients with native RVOT PR who underwent TPVR through April 30, 2022, at 11 U.S. CENTERS The primary outcome was a composite of hemodynamic dysfunction (PR greater than mild and RVOT mean gradient >30 mm Hg) and RVOT reintervention. RESULTS A total of 243 patients underwent TPVR at a median age of 31 years (Q1-Q3: 19-45 years). Cardiac diagnoses were tetralogy of Fallot (71%), valvular pulmonary stenosis (21%), and other (8%). Acute technical success was achieved in all but 1 case. Procedural serious adverse events occurred in 4% of cases, with no device embolization or death. Hospital length of stay was 1 day in 86% of patients. Ventricular arrhythmia prompting treatment occurred in 19% of cases. At a median follow-up of 13 months (Q1-Q3: 8-19 months), 98% of patients had acceptable hemodynamic function. Estimated freedom from the composite clinical outcome was 99% at 1 year and 96% at 2 years. Freedom from TPVR-related endocarditis was 98% at 1 year. Five patients died from COVID-19 (n = 1), unknown causes (n = 2), and bloodstream infection (n = 2). CONCLUSIONS In this large multicenter real-world experience, short-term clinical and hemodynamic outcomes of self-expanding TPVR therapy were excellent. Ongoing follow-up of this cohort will provide important insights into long-term outcomes.
Goldstein et al. (2024) conducted an observational in Native right ventricular outflow tract pulmonary regurgitation (n=243). Transcatheter pulmonary valve replacement with self-expanding Harmony valve was evaluated on Composite of hemodynamic dysfunction (PR greater than mild and RVOT mean gradient >30 mm Hg) and RVOT reintervention. Transcatheter pulmonary valve replacement with a self-expanding valve showed excellent short-term outcomes, with 99% estimated freedom from hemodynamic dysfunction and RVOT reintervention at 1 year.
Synapse has enriched 10 related papers. Consider them for comparative context: